Table 2.
Multivariable competing risks regression analysis by cause of death
| SEER | SEER-medicare | |||
|---|---|---|---|---|
| Variable | SDHR (95% CI) | P Value | SDHR (95% CI) | P Value |
| Endometrial cancer mortality | ||||
| Age at diagnosis, per year | 1.03 (1.03–1.04) | <.001 | 1.02 (1.01–1.04) | <.001 |
| Race (referent: white/other) | ||||
| Black | 1.67 (1.41–1.97) | <.001 | 1.37 (1.05–1.80) | .02 |
| Married (referent: no) | ||||
| Yes | 0.93 (0.84–1.02) | .10 | 0.96 (0.82–1.12) | .57 |
| SES (referent: lower) | ||||
| Higher* | 0.97 (0.89–1.06) | .50 | 1.01 (0.86–1.18) | .92 |
| Stage (referent: IA) | ||||
| IB | 2.14 (1.91–2.39) | <.001 | 2.35 (1.98–2.79) | <.001 |
| IIA/II NOS | 3.17 (2.78–3.60) | <.001 | 3.48 (2.83–4.27) | <.001 |
| II | 3.46 (2.88–4.16) | <.001 | 3.78 (2.96–4.84) | <.001 |
| Grade (referent: 1) | ||||
| 2 | 2.22 (1.95–2.53) | <.001 | 2.56 (2.05–3.19) | <.001 |
| 3 | 6.10 (5.33–6.97) | <.001 | 6.40 (5.12–7.97) | <.001 |
| Lymphadenectomy (referent: 0 nodes) | ||||
| 1–10 nodes | 0.87 (0.78–0.98) | .02 | 1.13 (0.94–1.35) | .18 |
| >10 nodes | 0.81 (0.73–0.91) | .003 | 0.99 (0.83–1.18) | .93 |
| Charlson comorbidity index (referent: 0) | ||||
| 1 | NA | NA | 0.97 (0.78–1.21) | .79 |
| >1 | NA | NA | 1.09 (0.77–1.55) | .63 |
| Noncancer mortality | ||||
| Age at diagnosis, per y | 1.08 (1.08–1.09) | <.001 | 1.09 (1.08–1.10) | <.001 |
| Race (referent: white/other) | ||||
| Black | 1.28 (1.13–1.45) | <.001 | 1.13 (0.94–1.36) | .20 |
| Married (referent: no) | ||||
| Yes | 0.75 (0.71–0.79) | <.001 | 0.76 (0.69–0.83) | <.001 |
| SES (referent: lower) | ||||
| Higher* | 0.95 (0.91–1.00) | .07 | 0.94 (0.86–1.02) | .16 |
| Stage (referent: IA) | ||||
| IB | 1.12 (1.05–1.20) | <.001 | 1.05 (0.95–1.16) | .34 |
| IIA/II NOS | 1.11 (1.01–1.22) | .03 | 1.06 (0.92–1.23) | .43 |
| II | 1.04 (0.85–1.27) | .70 | 1.05 (0.84–1.31) | .67 |
| Grade (referent: 1) | ||||
| 2 | 1.02 (0.96–1.08) | .49 | 1.01 (0.92–1.10) | .92 |
| 3 | 0.93 (0.86–1.00) | .05 | 0.91 (0.81–1.03) | .14 |
| Lymphadenectomy (referent: 0 nodes) | ||||
| 1–10 nodes | 0.88 (0.82–0.94) | <.001 | 0.90 (0.81–1.00) | .06 |
| >10 nodes | 0.76 (0.71–0.81) | <.001 | 0.79 (0.71–0.88) | <.001 |
| Charlson comorbidity index (referent: 0) | ||||
| 1 | NA | NA | 1.62 (1.45–1.82) | <.001 |
| >1 | NA | NA | 3.31 (2.74–4.01) | <.001 |
| Second cancer mortality | ||||
| Age at diagnosis, per y | 1.03 (1.03–1.04) | <.001 | 1.03 (1.02–1.04) | <.001 |
| Race (referent: white/other) | ||||
| Black | 1.40 (1.17–1.66) | <.001 | 1.34 (0.97–1.83) | .07 |
| Married (referent: no) | ||||
| Yes | 0.96 (0.88–1.05) | .35 | 1.00 (0.85–1.18) | .97 |
| SES (referent: lower) | ||||
| Higher* | 1.06 (0.98–1.15) | .16 | 0.92 (0.77–1.08) | .30 |
| Stage (referent: IA) | ||||
| IB | 1.08 (0.96–1.21) | .18 | 1.17 (0.97–1.42) | .10 |
| IIA/II NOS | 1.34 (1.16–1.54) | <.001 | 1.48 (1.15–1.91) | .002 |
| II | 1.25 (0.96–1.63) | <.001 | 1.72 (1.24–2.39) | .001 |
| Grade (referent: 1) | ||||
| 2 | 1.18 (1.07–1.29) | <.001 | 1.22 (1.02–1.47) | .03 |
| 3 | 1.42 (1.26–1.60) | <.001 | 1.67 (1.35–2.07) | <.001 |
| Lymphadenectomy (referent: 0 nodes) | ||||
| 1–10 nodes | 1.02 (0.91–1.13) | .77 | 0.83 (0.68–1.01) | .06 |
| >10 nodes | 0.84 (0.76–0.94) | .002 | 0.83 (0.69–1.01) | .06 |
| Charlson Comorbidity Index (referent: 0) | ||||
| 1 | NA | NA | 1.14 (0.90–1.44) | .28 |
| >1 | NA | NA | 0.92 (0.59–1.43) | .70 |
Abbreviations: CI = confidence interval; NA = not applicable; NOS = not otherwise specified; SDHR = subdistribution hazard ratio; SEER = Surveillance, Epidemiology, and End Results; SES = socioeconomic status.
*
Higher SES = above $47,070 annual salary.